Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...
Please provide your email address to receive an email when new articles are posted on . Radiographic parameters did not correlate with function after conservative treatment of distal radius fractures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback